1. Home
  2. WIA vs DTIL Comparison

WIA vs DTIL Comparison

Compare WIA & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Inflation-Linked Income Fund

WIA

Western Asset Inflation-Linked Income Fund

HOLD

Current Price

$8.14

Market Cap

189.4M

Sector

Finance

ML Signal

HOLD

Logo Precision BioSciences Inc.

DTIL

Precision BioSciences Inc.

HOLD

Current Price

$7.01

Market Cap

185.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WIA
DTIL
Founded
2003
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
189.4M
185.3M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
WIA
DTIL
Price
$8.14
$7.01
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$45.00
AVG Volume (30 Days)
36.7K
272.9K
Earning Date
01-01-0001
05-14-2026
Dividend Yield
12.29%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,070,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.95
$3.53
52 Week High
$8.54
$8.82

Technical Indicators

Market Signals
Indicator
WIA
DTIL
Relative Strength Index (RSI) 50.79 45.14
Support Level $8.13 $6.58
Resistance Level $8.24 $7.84
Average True Range (ATR) 0.04 0.60
MACD -0.00 -0.10
Stochastic Oscillator 50.00 15.02

Price Performance

Historical Comparison
WIA
DTIL

About WIA Western Asset Inflation-Linked Income Fund

Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.

About DTIL Precision BioSciences Inc.

Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).

Share on Social Networks: